Literature DB >> 3207373

Reaction of rheumatoid factors with IgG3 monoclonal anti-Rh(D) antibodies: more frequent reactivity to a monoclonal antibody of the Gm allotype G3m(5) in rheumatoid patients negative for G3m(5).

A H Puttick1, E A Williamson, A H Merry, B M Kumpel, K M Thompson, V E Jones.   

Abstract

Human monoclonal anti-Rh(D) antibodies of known IgG isotype and Gm allotype were bound to erythrocytes and then used as the target IgG antigens for rheumatoid factors (RFs) in a direct haemagglutination test. When serum samples from patients with rheumatoid arthritis (RA) were tested for RF specificity towards these IgG monoclonal anti-D antibodies the incidence and titre of reactivity towards an IgG3 monoclonal anti-D antibody was considerably greater than for a polyclonal anti-D antibody of the same Gm allotype, G3m(5). This difference was not explained by the amount of each anti-D antibody which bound to erythrocytes. Furthermore, when patients with RA were divided into groups according to their Gm phenotype, sera from a greater proportion of patients negative for the phenotype G3m(5) reacted to the G3m(5) monoclonal anti-D antibodies than sera from those patients positive for this allotype. Analysis of RF reactivities towards two IgG3 and three IgG1 monoclonal anti-D antibodies, each with different Gm allotypic epitopes, indicated, however, that individual serum samples contained RFs with a spectrum of specificities; some sera appeared to react to a single set of Gm alleles, whereas others also reacted to isotypic or iso-allotypic epitopes, or both. Our data suggest that RFs with specificity for Gm allotypes do not arise in patients who carry that particular allotype owing to tolerance induced in fetal-neonatal life. Conversely, RFs with apparent specificity for a Gm allotype formed in patients negative for that allotype may be reacting to a closely related but different epitope. Final proof requires precise specificities for each RF formed, and IgG3 monoclonal anti-D antibodies would be useful reagents for this purpose.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3207373      PMCID: PMC1003628          DOI: 10.1136/ard.47.11.898

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  22 in total

1.  Relation between Gm types and hemagglutinating substances in rheumatoid sera.

Authors:  M HARBOE
Journal:  Acta Pathol Microbiol Scand       Date:  1960

2.  In vitro development of human monoclonal antibody-secreting plasmacytomas.

Authors:  A Doyle; T J Jones; J L Bidwell; B A Bradley
Journal:  Hum Immunol       Date:  1985-07       Impact factor: 2.850

3.  Production of human monoclonal IgG and IgM antibodies with anti-D (rhesus) specificity using heterohybridomas.

Authors:  K M Thompson; M D Melamed; K Eagle; B D Gorick; T Gibson; A M Holburn; N C Hughes-Jones
Journal:  Immunology       Date:  1986-05       Impact factor: 7.397

4.  Estimation of the relative avidity of 19S IgM rheumatoid factor secreted by rheumatoid synovial cells for human IgG subclasses.

Authors:  D L Robbins; J Skilling; W F Benisek; R Wistar
Journal:  Arthritis Rheum       Date:  1986-06

5.  Hidden rheumatoid factors with specificity for native gamma globulins.

Authors:  J C Allen; H G Kunkel
Journal:  Arthritis Rheum       Date:  1966-12

6.  Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity.

Authors:  B Diamond; M D Scharff
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

7.  A quantitative antiglobulin test for IgG for use in blood transfusion serology.

Authors:  A H Merry; E E Thomson; V I Rawlinson; F Stratton
Journal:  Clin Lab Haematol       Date:  1982

8.  When does rheumatoid disease start?

Authors:  K Aho; T Palosuo; V Raunio; P Puska; A Aromaa; J T Salonen
Journal:  Arthritis Rheum       Date:  1985-05

9.  Chronic arthritis associated with the presence of intrasynovial rubella virus.

Authors:  R Grahame; R Armstrong; N Simmons; J M Wilton; M Dyson; R Laurent; R Millis; C A Mims
Journal:  Ann Rheum Dis       Date:  1983-02       Impact factor: 19.103

10.  An idiotypic complementarity between rheumatoid factor and anti-peptidoglycan antibodies?

Authors:  P M Johnson; K K Phua; H B Evans
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

View more
  2 in total

1.  Heteroclitic polyclonal and monoclonal anti-Gm(a) and anti-Gm(g) human rheumatoid factors react with epitopes induced in Gm(a-), Gm(g-) IgG by interaction with antigen or by nonspecific aggregation. A possible mechanism for the in vivo generation of rheumatoid factors.

Authors:  R C Williams; C C Malone; P Casali
Journal:  J Immunol       Date:  1992-09-01       Impact factor: 5.422

2.  Predicting anti-RhD titers in donors: Boostering response and decline rates are personal.

Authors:  Anneke S de Vos; C Ellen van der Schoot; Dimitris Rizopoulos; Mart P Janssen
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.